Population Pharmacokinetics of Tigecycline: A Systematic Review
Authors:
Open Access
- 1 June 2022
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 1885-1896
Abstract
Although tigecycline is widely used in clinical practice, its efficiency and optimal dosage regimens remain controversial. The purpose of this article was to help guide tigecycline dosing in different patient subpopulations through comparing the published population pharmacokinetic models of tigecycline, as well as summarizing and determining the potential covariates that markedly influence tigecycline pharmacokinetics. In this review, literature was systematically searched from the PubMed database from inception to March 2022. The articles focusing on population pharmacokinetics for tigecycline in healthy volunteers or patients were included; finally, a total of eight studies were included in this review. NONMEM methods were used in five studies to generate the population pharmacokinetic models. Tigecycline pharmacokinetics were mostly described by a two-compartment model in these included studies. Estimated clearance and volumes of distribution of tigecycline at steady state (Vss) varied widely in different target patient populations, with a range of 7.5– 23.1 L/h and 212.7– 1087.7 L, respectively. Body-weight and creatinine clearance were the most important predictors of clearance in these studies, while other predictors include age, gender, bilirubin and aspartate aminotransferase. In conclusion, this review showed the large variability of tigecycline population pharmacokinetics, which can provide guide dosing in different target populations. For clinicians, the individual dosing adjustment should be based not only on the indication and pathogen susceptibility but also on the potential important predictors. However, more studies were needed to confirm the necessity of modified dosage regimens in different patient subpopulations.Keywords
This publication has 35 references indexed in Scilit:
- Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority TrialsClinical Infectious Diseases, 2012
- How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamicsInternational Journal of Antimicrobial Agents, 2012
- Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired PneumoniaAntimicrobial Agents and Chemotherapy, 2010
- Clinical Pharmacokinetics and Pharmacodynamics of TigecyclineClinical Pharmacokinetics, 2009
- Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpointInternational Journal of Antimicrobial Agents, 2009
- Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2006
- TigecyclineJournal of Antimicrobial Chemotherapy, 2005
- Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNAJournal of Antimicrobial Chemotherapy, 2004